You are here: Industry Insights > QuadraMune

News List

Therapeutic Solutions International Identifies and Files Patent on Combination Effects Between its Nutraceutical QuadraMune™ and Ivermectin in Animal Models of COVID-19 Pathology prnewswire
September 23, 2021
Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today new data demonstrating positive effects when its commercially available nutraceutical, QuadraMune™...
Therapeutic Solutions Announces Positive QuadraMune Clinical Trial Data americanpharmaceuticalreview
December 18, 2020
Therapeutics Solution International announced new data from its clinical trial demonstrating an almost doubling of immune cell activity in healthy volunteers which were ingesting QuadraMune™ daily for a week.
Campbell Neurosciences Files Patent on QuadraMune for Major Depressive Disorder americanpharmaceuticalreview
December 10, 2020
Therapeutics Solution International announced new data suggesting the possibility that QuadraMune™ may mediate neuroprotective activity through preserving the ability of regenerative brain cells to proliferate subsequent to psychological stress.
Therapeutic Solutions Initiates 500 Volunteer COVID-19 Prevention Clinical Trial Using QuadraMune americanpharmaceuticalreview
June 17, 2020
Therapeutics Solutions announced the initiation of a clinical trial aimed at demonstrating safety and efficacy of its immune-boosting formulation QuadraMune™.